Triple-Negative Breast Cancer  

Oleh:

Foulkes, William D. ; Smith, Ian E. ; Reis-Filho, Jorge S.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 363 no. 20 (Nov. 2010), page 1938-1948.
Topik: CANCER; Breast Cancers

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2010.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

A PubMed search of the medical literature shows that the first mention of “triple-negative” breast cancer was in October 2005; since then, the term has appeared in more than 600 publications.1 This increase reflects the growing recognition of the importance of triple-negative breast cancer (see the Glossary for this and other key terms) by oncologists, pathologists, and geneticists, as well as by the approximately 12 to 17% of women with breast cancer who have triple-negative breast cancer. As a group, patients with triple-negative tumors have a relatively poor outcome and cannot be treated with endocrine therapy or therapies targeted to human epidermal growth factor receptor type 2 (HER2). A close cousin of triple-negative breast cancer is basal-like breast cancer (synonymous terms include “basal-type,” “basal-epithelial phenotype,” “basal breast cancer,” and “basaloid breast cancer”). This molecular subtype of breast cancer is characterized by a gene-expression profile that is similar to that of the basal–myoepithelial layer of the normal breast.2 Immunohistochemical markers have been used as a surrogate for this profile. The multiplicity of names reflects an underlying uncertainty as to the true nature of this entity.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali